

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Chimeric Therapeutics Limited (ASX: CHM)
ABN:	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr George Matcham
Date of Last Notice:	30 March 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Held via broker nominee account.														
Date of change	4 July 2022														
No. of securities held prior to change	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: right;">2,750,000</td> </tr> <tr> <td>Indirect</td> <td style="text-align: right;">658,730</td> <td style="text-align: right;">158,730</td> </tr> <tr> <td>Total</td> <td style="text-align: right;">658,730</td> <td style="text-align: right;">2,908,730</td> </tr> </tbody> </table>				Shares	Options	Direct	-	2,750,000	Indirect	658,730	158,730	Total	658,730	2,908,730
	Shares	Options													
Direct	-	2,750,000													
Indirect	658,730	158,730													
Total	658,730	2,908,730													
Class	Fully Paid Ordinary Shares														
Number acquired	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Indirect</td> <td style="text-align: right;">342,070</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: right;">342,070</td> <td style="text-align: center;">-</td> </tr> </tbody> </table>				Shares	Options	Direct	-	-	Indirect	342,070	-	Total	342,070	-
	Shares	Options													
Direct	-	-													
Indirect	342,070	-													
Total	342,070	-													

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.098 per share (average)		
No. of securities held after change		Shares	Options
	Direct	-	2,750,000
	Indirect	1,000,800	158,730
	Total	1,000,800	2,908,730
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market Trade		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

+ See chapter 19 for defined terms.

If prior written clearance was provided, on what date was this provided?	N/A
---	-----



The CFO Solution

+ See chapter 19 for defined terms.